Merck’s antiviral drug meets main goal in late-stage trial



Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.


The trial evaluated the efficacy and safety of the drug, letermovir, for prevention of cytomegalovirus infection in adult recipients of a stem cell transplant.


The drug was administered once daily, either in oral tablet or IV formulation, to patients and continued for about 100 days after the transplant.


Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.



(Reporting by Shailesh Kuber; Editing by Martina D’Couto)

Source: Reuters Health